MedTrace Logo

Effect of Hyperuricaemia on Chronic Renal Disease

NCT03425708 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2018-02-07

No results posted yet for this study

Summary

To investigate the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention

Conditions

  • Hyperuricemia
  • Chronic Renal Disease

Interventions

DRUG

20mg Febuxostat

Participants take 20mg febuxostat pill once a day for at least six months.

DRUG

40mg Febuxostat

Participants take 40mg febuxostat pill once a day for at least six months.

Sponsors & Collaborators

  • The First People's Hospital of Xuzhou

    collaborator OTHER

  • The Affiliated Hospital of Xuzhou Medical University

    lead OTHER

Principal Investigators

  • Dong Sun, MD · The Affiliated Hospital of Xuzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03425708 on ClinicalTrials.gov